Vonicog Alfa Application Scope

Vonicog alfa, also known as von Willebrand factor (Recombinant), is indicated for the on-demand treatment and control of bleeding episodes, as well as the perioperative management of bleeding in adult patients (18 years and older) with von Willebrand disease (VWD). It is the first and currently the only recombinant von Willebrand factor product available globally.

Vonicog Alfa Package Insert

Ingredients: Recombinant von Willebrand factor (rVWF).
Properties: Vonicog alfa includes the full range of VWF multimers, including ultra-large multimers (ULMs), and has a prolonged half-life, effectively supporting replacement therapy for VWD.
Specification: Available as a lyophilized powder for injection.
Packaging Specification: Provided in single-use vials containing specified units of rVWF.
Storage: Store in accordance with the manufacturer’s guidelines, typically in a refrigerated environment.
Expiry Date: Refer to the product’s packaging for expiration information.
Executive Standard: Manufactured following international pharmaceutical standards for recombinant proteins.
Approval Number: Pending specific regional regulatory approval details.
Date of Revision: Refer to the latest prescribing information for the most recent revision date.
Manufacturer: Takeda Pharmaceutical Company Limited.

Guidelines For The Use Of Vonicog Alfa

Dosage and Administration: The dosage should be individualized based on the patient’s weight, the severity of VWF deficiency, and the location and extent of bleeding. Administration may require an initial loading dose followed by maintenance dosing, with or without recombinant factor VIII, depending on the clinical scenario. Healthcare professionals should consult the detailed prescribing information for specific dosing guidelines.
Vonvendi Side Effects: Common adverse reactions may include hypersensitivity reactions, thromboembolic events, and development of neutralizing antibodies. Patients should be monitored for signs of allergic reactions and thrombosis during treatment.
Contraindications: Vonicog alfa is contraindicated in patients with known hypersensitivity to any of its components or to mouse or hamster proteins.
Precautions: Caution is advised in patients with a history of thromboembolic events, as rVWF may increase the risk of thrombosis. Regular monitoring of VWF and factor VIII levels is recommended to adjust dosing appropriately.

Vonicog Alfa Interactions

Drug Interactions: No specific drug interaction studies have been conducted with Vonicog alfa. However, concomitant use with other coagulation factors or antifibrinolytic agents should be approached with caution due to the potential increased risk of thrombosis.

For comprehensive prescribing information, healthcare professionals should refer to the official prescribing guidelines provided by the manufacturer.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from HongKong DengYue Medicine. It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.